About
NRDL+ is a strategic health policy intelligence platform focused on China’s evolving coverage and financing architecture for innovative medical technologies.
What began as independent policy commentary has evolved into a structured intelligence platform connecting system-level reform dynamics and implementation realities to real-world market access, portfolio, and capital allocation decisions. We interpret cross-layer regulatory signals and execution dynamics — across basic medical insurance, commercial health insurance, payment reform, and emerging coverage mechanisms — clarifying their commercial and strategic consequences for global life sciences leaders.
Access360, NRDL+’s Premier Membership program, provides ongoing executive briefings, implementation deep dives, and interpretive intelligence designed to support decision-making at the asset, portfolio, and organizational levels. Complementary Masterclass programs and Strategy Sessions enable deeper leadership alignment and application.
NRDL+ Executive Debrief is powered by bizi LLC, a New Jersey–based consultancy with over a decade of experience advising life sciences leadership teams on pricing, reimbursement, and market access across global and local markets.
People
Kelly Ke
Founder, bizi LLC | Architect of NRDL+
Kelly Ke is the founder of bizi LLC and the architect of NRDL+, a strategic intelligence platform focused on China’s evolving coverage and health financing architecture.
Prior to founding bizi LLC, Kelly spent a decade as an award-winning senior advisor in Deloitte US’s Life Sciences practice. Since then, she has led bizi’s work advising global life sciences leadership teams on pricing, reimbursement, and market access strategy across both global and local contexts.
Operating at the intersection of health policy and strategic decision-making, Kelly provides structured interpretation of cross-layer regulatory signals within China’s evolving coverage and financing system — translating system-level reform dynamics into actionable implications for market access execution, portfolio strategy, and capital allocation decisions.
Her co-authored policy analysis has been published in Caixin, contributing to industry dialogue on China’s evolving multi-layer coverage framework. Her work is followed by executives from over two-thirds of the world’s top 30 pharmaceutical companies, as well as leading biotechs, insurers, hospital groups, and academic institutions.
Through Access360, Masterclass programs, and Strategy Sessions, Kelly supports leadership teams navigating regulatory and implementation uncertainty within China’s multi-layer coverage system.
She collaborates with a curated network of leading China policy and industry experts, integrating field-grounded insight on policy design and execution into the NRDL+ intelligence framework.
Originally from Beijing, Kelly holds master’s degrees from the University of Southern California and the University of Utah, and a postgraduate certificate in International Health Technology Assessment (HTA) and Reimbursement from the University of Sheffield.